logo
FDA approves first cervical cancer screening device that can be used at home, company says

FDA approves first cervical cancer screening device that can be used at home, company says

Yahoo09-05-2025

To get screened for cervical cancer, patients in the United States may no longer need to put their feet in those awkward stirrups, brace for the uncomfortable speculum or even take the time off from work for an in-person doctor's appointment.
Soon, they will have the option to collect their own vaginal samples for screening from home – instead of a health care provider doing it for them.
The US Food and Drug Administration has approved the first at-home self-collection device for cervical cancer screening in the United States, called the Teal Wand, according to the women's health company Teal Health. Last year, the FDA gave the company's Teal Wand 'breakthrough device' status, allowing the agency to review it on a faster timeline.
Teal Wand, which will be provided in Teal Health's at-home self-collection kit, will require a prescription. Self-collected samples using the Wand are then mailed to a lab to be tested for HPV, the company announced Friday. Most cervical cancers are caused by human papillomavirus or HPV, and screening for HPV can help identify women who may be at risk of developing cervical cancer.
Typically, when screening for cervical cancer, gynecologists collect samples for HPV testing, cervical cytology or both. Cervical cytology, also known as a Pap test or Pap smear, involves examining cervical cells for changes to detect precancerous or cancerous cells. The HPV test checks cells for infection with the high-risk types of HPV that can cause cervical cancer.
Last year, the FDA greenlit similar self-collection cervical cancer screening kits for use in a medical setting, such as at a doctor's office, an urgent care or even a mobile clinic. At the time, two health care businesses – biotechnology company Roche and medical technology firm Becton, Dickson and Company – said the FDA had approved the use of self-collected samples with their respective HPV tests.
The Teal Health at-home kit allows a patient to collect their sample using the Teal Wand, which is then processed on Roche's HPV test, said Kara Egan, Teal Health's CEO. But a major difference is that the Teal Wand is approved to be used at home, so patients don't have to travel to or make time for in-person doctor appointments.
To use Teal Health's new self-collection kit, 'you request a kit at the Teal website, meet with a provider who prescribes the kit, then comfortably and privately collect at home and mail to the lab to process on the Roche Cobas HPV test,' Egan said.
'The results are then reviewed by a clinician and shared back,' she said. 'If the results are positive, a provider will meet with you and refer you to any required follow-up.'
Clinical trial data from Teal Health has found that self-collection with the Teal Wand has the same accuracy for cervical cancer screening as when a health care provider collects a sample, Egan said.
'It's the same test, same accuracy, but you can comfortably do it from home,' she said. 'It gives women more options, and with telehealth, we see more options to get access to care.'
Teal Health plans to begin shipping its at-home self-collection kits in June, Egan said, starting in California before expanding nationwide. A waitlist is available at the company's website.
Teal Health has been in talks with health insurance companies about having the self-collection kit covered, Egan added, and for people who don't have insurance, the cost of the kit will be announced within the next month.
The American Cancer Society applauded the new FDA approval.
'Despite the benefits of cervical cancer screening, not all eligible are screened regularly,' Dr. William Dahut, the society's chief scientific officer, said in an email Friday. 'Most cervical cancers are found in people who have never had a cervical cancer screening test or who have not had one recently. That's why today's Food and Drug Administration's announcement approving the first at-home test to screen for cervical cancer as an additional cancer screening method for this potentially deadly disease will make a huge impact.'
Some of the most important steps women can take to help reduce their risk for cervical cancer, according to the US Centers for Disease Control and Prevention, are to get vaccinated against HPV, avoid smoking, use condoms during sex, have regular screening tests and check with their doctor if their test results are not normal.
It's estimated that about 1 in 4 adults are not up to date on cervical cancer screening recommendations, according to data from 2021.
'Some women are scared of a traditional pap smear or find the process uncomfortable, as a result they put off this vital test,' Dr. Ami Vaidya, co-chief of gynecologic oncology at Hackensack University Medical Center's John Theurer Cancer Center, said in a news release Friday.
The newly approved at-home screening device 'could be an important tool in getting more women regularly screened, especially those that don't have access to a medical provider,' Vaidya said. 'Any type of test that helps detect cervical cancer is a win.'
The US Preventive Services Task Force recommends screening for cervical cancer with cervical cytology – also known as a Pap test or Pap smear – every three years for women ages 21 to 29. For women 30 to 65, the USPSTF recommends screening every three years with cervical cytology alone, every five years with high-risk HPV testing alone, or every five years with high-risk HPV testing in combination with cytology.
It's estimated that about 80% of people will get an HPV infection in their lifetime. HPV, a group of more than 150 viruses, is spread primarily through sexual contact and includes low-risk strains, which most often cause warts, and high-risk strains, which have been associated with an increased risk of certain cancers, such as cervical, anal, penile and oropharyngeal cancers. In most cases, HPV clears on its own within two years, but when the infection does not go away, health problems like cancer may occur.
Screening for cervical cancer remains important because early cases often may not have signs or symptoms. Advanced cases may cause abnormal vaginal bleeding or unusual discharge. Cervical cancer is treated in many ways, including surgery, chemotherapy and radiation therapy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

time2 hours ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

Should Kids Get the HPV Vaccine Earlier?
Should Kids Get the HPV Vaccine Earlier?

Medscape

time3 hours ago

  • Medscape

Should Kids Get the HPV Vaccine Earlier?

Recommending the human papillomavirus (HPV) vaccination to parents of 9- to 10-year-old children allowed clinicians to discuss cancer prevention and avoid the sticky subject of sexual activity that often comes up with older age groups, new research showed. The study, published in Pediatrics , also found that parents were generally open to having their 9- to 10-year-old children vaccinated for HPV. 'At ages 9-10, sexual activity was less salient, and HPV was the only vaccine to discuss,' said Caroline Tietbohl, PhD, an assistant professor in the Department of Family Medicine at the University of Colorado in Aurora, Colorado, and lead author of the study. 'This made discussions shorter and easier and also paid forward to the 11-year-old visit, where there was now one less vaccine to discuss.' HPV is the most common sexually transmitted infection in the US, with approximately 42 million people currently infected. The US CDC currently recommends the HPV series vaccine as part of routine vaccination beginning at age 11 years, but states that vaccination can start at age 9 years. The vaccine is highly effective for preventing several types of cancer, including cervical and oropharyngeal cancers. Two doses are recommended for most people who start the series before age 15 years, and three doses are recommended for those who start the series after age 15 years, as well as immunocompromised individuals. Yet only 40% of children between 9 years and 17 years of age have received at least one dose. Tietbohl said her team was motivated to conduct the research by persistently low completion rates of the HPV series despite strong evidence that the vaccine is safe and highly effective at preventing cancer. 'We anticipated that bringing up the HPV vaccine at this age could make the discussion easier by decoupling it from sexual activity and focusing on its purpose — cancer prevention — and this seems to have been true for many parents in our study,' Tietbohl said. She and her colleagues surveyed and interviewed pediatricians and staff between 2021 to 2022 at 17 clinics in Colorado and 16 in California. The practices were randomly assigned to either recommend the HPV vaccine to parents of the younger children or to continue at the current standard at ages of 11-12 years. Surveys assessed how the shift was implemented, while interviews provided more detail about any challenges or benefits observed. Prior to the intervention, none of the clinics had recommended the vaccine to younger patients, instead following the current standard recommendation. One month after the intervention, over 90% of clinicians in Colorado and 77% of those in California reported routinely recommending the vaccine to children at ages 9 years or 10 years. Most clinicians and staff in the intervention group reported that parents were largely receptive to the earlier recommendation, sometimes to the clinician's surprise. Many said they had expected parents to push back, assuming that discussions of the HPV vaccine would raise concerns about sexual activity or be met with hesitation. Instead, they found that conversations were easier at ages 9 years and 10 years because sexual activity was less of a consideration for parents at that age. Angela Myers, MD The findings build on evidence that parents may be more receptive when the discussion starts earlier, said Angela Myers, MD, professor of pediatrics and pediatric infectious diseases at the University of Missouri-Kansas City, who was not involved in the study. 'The earlier we get kids vaccinated against HPV, the better their immune response,' Myers said. 'Sexual activity becomes kind of a nonthought at age 9. That's as it should be because this is a cancer prevention vaccine.' Despite the positive response, some clinicians noted challenges, including electronic health record reminders that still reflected the older age recommendation, as well as occasional parental surprise at being offered the vaccine at a younger age. 'The main hitch was that some parents were not expecting to discuss the HPV vaccine until age 11 and had already promised their kids that the 9- or 10-year-old visit would not include shots,' Tietbohl said. The next phase of the research will focus on analyzing whether earlier vaccination improves rates of series completion by age 13 years, Tietbohl said. Myers said recommending the vaccine earlier could help improve vaccination rates by giving families more time to complete the series before adolescence. 'Every new study that gets published adds a little bit more to the story,' Myers said. 'Collectively, all of the data can help in saying, 'Perhaps we should take another look at this and perhaps we should change the language slightly.' Tietbohl and Myers did not report any relevant conflicts of interest. The study was supported by the National Cancer Institute of the National Institutes of Health.

Mailed Kits Beat Office Visits for Cervical Cancer Screening
Mailed Kits Beat Office Visits for Cervical Cancer Screening

Medscape

time3 hours ago

  • Medscape

Mailed Kits Beat Office Visits for Cervical Cancer Screening

Mailed self-collection kits and a telephone reminder helped increase cervical cancer screening (CCS) rates more than twice as much as telephone reminders for an office visit, according to new data from a randomized clinical trial in a safety-net population. The home kits paired with additional patient contact increased numbers even further. In a trial that included 2474 people overdue for CCS (94% of them from minority populations), participants randomized to a telephone reminder with a mailed self-collection kit had 41.1% participation compared to those with a phone reminder to come in for an office visit (17.4%). CCS rates were modestly higher (46.6%) when people received contact in addition to the telephone reminder and mailed self-collection kit for testing human papillomavirus (HPV). Self-collection with additional patient contact was designed to be different from self-collection with a telephone reminder in terms of the dose of patient interactions rather than content, minimizing potential contamination across the self-collection with telephone reminder and self-collection with additional patient contact groups. The study, led by Jane R. Montealegre, PhD, with the Department of Behavioral Science, The University of Texas MD Anderson Cancer Center in Houston, was conducted from February 20, 2020, to August 31, 2023, and published in JAMA Internal Medicine . Cervical Cancer Could be Eliminated in the US in 10-20 Years Estimates show that cervical cancer in the US could see national-level elimination in the next one to two decades if CCS rates hit 90%. However up-to-date screening has declined in recent years and was 75.2% in 2021, with rates notably lower among underserved populations, including women and people with a cervix who are uninsured or publicly insured, live in rural areas, and are from minority populations. The study researchers noted that the results in this trial, the PRESTIS trial, are consistent with the relative participation rates of previous trials. In a recent meta-analysis of 28 trials, Stefanie Costa and colleagues reported a 2.5-fold higher participation in screening with mailed self-collection vs usual care. 'Notably distinct from previous trials are the large screening proportions attained in the [self-collection (SC) group] (41.1%) and SC with patient navigation (46.6%) groups, as compared to the global estimate of 24% reported in the meta-analysis,' the authors wrote. In an accompanying editorial, Eve Rittenberg, MD, MA, with the Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues wrote that home self-collection 'has the potential to meaningfully reduce cervical cancer burden, especially among underserved populations.' They pointed out that self-collection has previously been studied in a clinical setting, where women can collect a sample privately without undergoing an invasive Pap smear and that 'self-collected HPV samples have similar specificity and sensitivity to clinician-collected samples.' But it hasn't been known whether the tests need to be performed in a clinic. Home Screening May Further Eliminate Barriers Montealegre's team shows that 'home self-collection demonstrates that people can adequately obtain usable samples in the privacy of their homes, as only 6% of samples were deemed inadequate for evaluation,' the editorialists wrote. Home-based screening, they explained, may further eliminate screening barriers for underserved populations with lower costs and fewer logistical hurdles. Additionally, screening via pelvic exam can be uncomfortable and may be culturally unacceptable for some. Pelvic exam-based screening may be particularly distressing to those who have experienced sexual trauma, they wrote. They pointed out that options for CCS are growing with the approval last month by the FDA of a home HPV self-collection kit, which will be available for clinical use within months. Self-collection of HPV samples is included in the World Health Organization's global strategy to eliminate cervical cancer by 2030, and the draft US Preventive Services Task Force CCS guidance now includes self-collection as an option. Future research should help determine whether more home self-collected HPV screening leads to higher rates of treating precancerous lesions and eventually lower cervical cancer rates, the editorialists wrote. They also noted that efforts to increase CCS rates should be accompanied by efforts to increase HPV vaccination rates. The research was funded through grants from the National Institute on Minority Health and Health Disparities and the National Cancer Institute through an MD Anderson Cancer Center Support Grant, the Dan L Duncan Comprehensive Cancer Center Support Grant, and the Hollings Cancer Center Support Grant. The authors reported having no relevant financial relationships. An editorialist, Cary Gross, MD, reported receiving grants from Johnson & Johnson and the National Comprehensive Cancer Network (with funding provided by AstraZeneca) outside the submitted work. No other disclosures were reported.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store